High-dose chlorozotocin in lung cancer: A southwest oncology group phase II study

C. D. Haas, R. L. Stephens, R. M. Bukowski, W. J. Stuckey, J. D. McCracken, R. G. Gagliano, D. E. Lehane, R. P. Pugh

Research output: Contribution to journalArticlepeer-review

4 Scopus citations

Abstract

Chlorozotocin was administered as an iv bolus at a dose of 200-225 mg/m2 every 6 weeks for good-risk patients (100 mg/m2 for poor-risk patients) with lung cancer. Only three of 71 fully evaluable patients responded; 12 had stable disease. Myelosuppression was acceptable and no other dose-limiting toxic effects were reported. Chlorozotocin is inactive in non-small cell lung cancer.

Original languageEnglish (US)
Pages (from-to)705-707
Number of pages3
JournalCancer Treatment Reports
Volume67
Issue number7-8
StatePublished - 1983

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'High-dose chlorozotocin in lung cancer: A southwest oncology group phase II study'. Together they form a unique fingerprint.

Cite this